Cher, C Y <br/><br/>
Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.  [electronic resource] 

 -  Blood cancer journal  07 2016 
 - e442 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>2044-5385 
<br/><br/><label>Standard No.: </label>10.1038/bcj.2016.51  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Combined Modality Therapy<br/>Core Binding Factors--genetics<br/>DNA Methylation<br/>DNA Mutational Analysis<br/>DNA-Binding Proteins--genetics<br/>Dioxygenases<br/>Female<br/>Hematopoietic Stem Cell Transplantation--methods<br/>High-Throughput Nucleotide Sequencing<br/>Humans<br/>Leukemia, Myeloid, Acute--genetics<br/>Male<br/>Middle Aged<br/>Mutation<br/>Prognosis<br/>Proto-Oncogene Proteins--genetics<br/>Proto-Oncogene Proteins c-kit--genetics<br/>Signal Transduction<br/>Survival Analysis<br/>Translocation, Genetic<br/>Transplantation, Homologous<br/>Young Adult